Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations.
Cancers and other non-communicable diseases have become significant global health and development threats. In 2019, nearly 23.6 million new cancer cases and 10 million cancer deaths were reported worldwide. The world is getting used to cancer, but we shouldn’t accept it. There is a dire need to discover practical solutions and develop diagnostic tools to fight against this ever-increasing burden.
It’s when BostonGene comes into the picture. This US-based biotechnology company conducts research and clinical trials and has developed advanced biomedical software to analyze patients for cancer and help suggest them the best treatment possible.
To know more about BostonGene, consider going through the article.
BostonGene – Company Highlights
| Company Name | BostonGene |
|---|---|
| Headquarters | Waltham, Massachusetts, United States |
| Sector | Biotechnology |
| Founders | Andrew Feinberg |
| Founded | 2015 |
| Website | Bostongene.com |
About BostonGene
BostonGene – Industry
BostonGene – Founders and Team
BostonGene – Startup Story
BostonGene – Mission and Vision
BostonGene – Business Model
BostonGene – Revenue Model
BostonGene – Products and Services
BostonGene – Funding and Investors
BostonGene – Growth
BostonGene – Partners
BostonGene – Awards and Achievements
BostonGene – Competitors
About BostonGene
Based in Waltham, Massachusetts, BostonGene Corporation uses biomedical software for advanced patient analysis and personalized therapeutic decision-making for patients to help them fight against cancer. It has discovered, developed, and patented a holistic approach to cancer treatment. The company’s platform lets individual patients know the optimal therapy combination, mainly focusing on immune-targeted therapies.
BostonGene serves customers all over the United States.
BostonGene – Industry
The primary industry BostonGene serves is the Biotechnology industry. The global market size of the Biotechnology industry was roughly $1,224.31 billion in 2022. It’s expected to grow $3,210.71 billion by 2030 at a noteworthy CAGR of 12.8% during 2023-30. One critical market growth driving factor is the growing biotechnology sector in developing countries like India, China, and Japan due to favorable government initiatives.
Moreover, during the Covid-19 pandemic, there was a dire need for all countries to discover novel solutions and develop vaccines and diagnostic tools to fight against the disease. Talking about the top-ranked biotechnology companies, AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Inc., Sanofi, and Biogen are some key players.
BostonGene – Founders and Team
Andrew Feinberg is the founder of BostonGene.
Andrew Feinberg
In addition to being the founder, Andrew Feinberg is the current President and CEO of the company. He earned a bachelor’s Degree from Bentley University and MBA from The Wharton School. He has worked as a Consultant at Bain & Company. Andrew also holds the position of CEO and Chairman at Netcracker Technology.
BostonGene Team
- Alexander Bagaev – Vice President of Product Development
- Brittan McClanahan – Vice President of Sales
- Nathan Fowler – Chief Medical Officer
BostonGene is a team of around 300 employees.
BostonGene – Startup Story
BostonGene was founded by Andrew Feinberg in 2015. Under Andrew’s solid leadership, BostonGene established itself as a market leader in the biotechnology industry. The company collaborated with Washington University in St. Louis for Cancer Research in 2019 and Kidney Cancer Research in 2020. In the same year, in 2020, BostonGene and Transgene, NEC collaborated for clinical trials for Patients with Ovarian and Head & Neck Cancers.
The company announced the publication in the Blood Cancer Journal in August 2021. And a year later, BostonGene expanded its testing capabilities to predict patient response to Immunotherapy in February 2022.
Later, in January 2023, MD Anderson EGFR Classification was licensed by BostonGene and Tempus for providing new insight into atypical mutations in lung cancer. The company announced the launch of its CLIA-certified and CAP-accredited Liquid Biopsy, Spatial Proteomics, and Immunoprofiling solutions in June 2023.
BostonGene – Mission and Vision
BostonGene aims to power healthcare’s transition to personalized medicine with its AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics.
BostonGene – Business Model
BostonGene’s AI-based molecular and immune profiling software sequences both DNA and RNA via a patented process, allowing physicians to understand information about the cancerous cells and the macro-environment in which they exist. The BostonGene Tumor Portrait Test help reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended treatments. Once the analysis is completed, the BostonGene Tumor Test develops a personalized roadmap for therapeutic decision-making for each cancer patient.
BostonGene – Revenue Model
BostonGene’s revenue model involves offering its AI-based molecular and immune profiling platform to empower healthcare providers to match individual patients with the most appropriate treatments for their health conditions. In addition, healthcare professionals can use the information to prescribe the best drugs, understand their potential side effects, and determine how surgery can impact the areas surrounding the tumor.
BostonGene – Products and Services
BostonGene is the provider of the following:
- BostonGene Tumor Portrait Test
- BostonGene Liquid Biopsy
- BostonGene Immunoprofiling
- BostonGene Spatial Proteomics
Moreover, the company has developed BioPharma, which offers Laboratory Solutions, Bioinformatics Services, and Industry Applications.
BostonGene
BostonGene – Funding and Investors
BostonGene has completed 2 funding rounds through which it raised $ 200 million. Its latest funding round – Series B Round, was conducted on April 6, 2022. NEC Corporation, Japan Industrial Partners, and Impact Investment Capital are some investors who back the company.
| Date | Round | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| April 6, 2022 | Series B | 3 | $150 million | NEC Corporation |
| April 25, 2019 | Series A | 1 | $50 million | NEC Corporation |
BostonGene – Growth
With $150 million raised in a Series B funding round, BostonGene became a unicorn with a multi-billion dollar valuation.
StartupTalky
BostonGene – Partners
BostonGene has partnered with the following leading cancer centers:
- Memorial Sloan Kettering Cancer Center
- Mayo Clinic
- Abramson Cancer Center of the University of Pennsylvania
- Brigham and Women’s Hospital
- Dana Farber Cancer Institute
- Mass General Hospital
- Mater Research
- Medical College of Wisconsin
- National Cancer Institute
BostonGene – Awards and Achievements
Some of the awards BostonGene has been honored with to date are as follows:
- Named one of Massachusetts’ Best Genetics and Bioinformatics Startups by BestStartup.us in 2021
- Recognized for its State-of-the-Art Technology in Cancer Research and Oncology by Cancer Cell in 2022
- Won a GRASP Advocate Choice Award for the 2023 ASCO Annual Meeting Poster in the Patient Advocacy Group Awards
BostonGene – Competitors
BostonGene has approximately 544 active competitors, and some of these are listed below:
- Benchling
- Insilico
- BioAge Labs
- Immuneering Corporation
- Arbutus Biopharma
FAQs
What does BostonGene do?
BostonGene Corporation uses biomedical software for advanced patient analysis and personalized therapeutic decision-making for patients to help them fight against cancer.
Who is the founder of BostonGene?
Andrew Feinberg is the founder of BostonGene.
Who are the main competitors of BostonGene?
The main competitors of BostonGene include Benchling, Insilico, BioAge Labs, Immuneering Corporation, and Arbutus Biopharma.
